Uterine fibroids are noncancerous growths of the uterus that often appear during childbearing years. Several companies in the United States are involved in the development and marketing of products related to the diagnosis, treatment, and management of uterine fibroids
December 2023:Gynesonics, a women's healthcare company focused on minimally invasive solutions for symptomatic uterine fibroids, raised $42.5 million in funding to expand the commercialization of its Sonata procedure.
June 2023:Viveve Medical, a company developing non-invasive radiofrequency energy treatments for feminine health issues, acquired Emsella for $100 million, strengthening its market position in women's intimate health solutions.
July 2023:US Food and Drug Administration (FDA) approved Acessa Health's Acessa® System for the treatment of heavy menstrual bleeding associated with uterine fibroids. This approval provides a novel minimally invasive option for women suffering from this condition.
April 2023:Myovant launched a Phase 3 clinical trial evaluating the efficacy and safety of relugolix (YELNO) for the treatment of pain and heavy menstrual bleeding associated with uterine fibroids. This study could lead to a new oral medication option for managing fibroid symptoms.
List of Uterine Fibroid Key Companies in the Market
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)